A Phase 3 Randomized Study of Selumetinib versus Carboplatin and Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

syn36360320

Created By NF Service nf-osi-service

studyName: A Phase 3 Randomized Study of Selumetinib versus Carboplatin and Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
dataStatus: Data Pending
initiative: Vision Restoration Initiative
studyLeads: Rob Avery
studyStatus: Active
diseaseFocus: Neurofibromatosis type 1
institutions: Children's Hospital of Philadelphia
fundingAgency: GFF
relatedStudies: syn36361151 syn21650488 syn21650476 syn36528589
studyFileviewId: syn36360328
syn36360325
syn36360326
syn36360328
syn36360327

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

A Phase 3 Randomized Study of Selumetinib versus Carboplatin and Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) page is loading…

A Phase 3 Randomized Study of Selumetinib versus Carboplatin and Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

syn36360320

Drop files to upload

A Phase 3 Randomized Study of Selumetinib versus Carboplatin and Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) page is loading…